EVEROLIMUS MSDS PDF

Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.

Author: Marr Zulkikinos
Country: Andorra
Language: English (Spanish)
Genre: Art
Published (Last): 22 November 2004
Pages: 342
PDF File Size: 1.61 Mb
ePub File Size: 20.82 Mb
ISBN: 376-7-65264-208-8
Downloads: 46103
Price: Free* [*Free Regsitration Required]
Uploader: Dat

Halothane The metabolism of Everolimus can be decreased when combined with Halothane. Amobarbital The metabolism of Everolimus can be increased when combined with Amobarbital. Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Everolimus.

Mirabegron The metabolism of Everolimus can be decreased when combined with Mirabegron. Ivosidenib The serum concentration of Everolimus can be increased when it is combined with Ivosidenib.

Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Everolimus. Crizotinib The metabolism of Everolimus can be decreased when combined with Crizotinib. Metronidazole The serum concentration of Everolimus can be increased when it is combined with Metronidazole.

Lorazepam The metabolism of Everolimus can be decreased when combined with Lorazepam. Nafcillin The metabolism of Everolimus can be increased when combined with Nafcillin. Morphine The metabolism of Everolimus can be decreased when combined with Morphine.

Warning and precautions People who are allergic to Everolimus should be disabled. Dicloxacillin The metabolism of Everolimus can be increased when combined with Dicloxacillin.

Clindamycin The metabolism of Everolimus can be decreased when combined with Clindamycin. Doxofylline The metabolism of Doxofylline can be decreased when combined with Everolimus.

Everolimus

Fluconazole The metabolism of Everolimus can be decreased when combined with Fluconazole. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Everolimus. Adverse reactions Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with concomitant use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression [10].

Fosphenytoin The metabolism of Everolimus can be increased when combined with Fosphenytoin.

Opium The metabolism of Everolimus can be decreased when combined with Opium. Hydrocodone The metabolism of Everolimus can be decreased when combined with Hydrocodone. Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Everolimus. everolmus

Inhibits cytokine-mediated lymphocyte proliferation. Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Everolimus.

Everolimus | C53H83NO14 – PubChem

Laniquidar The serum concentration of Everolimus can be increased when it is combined with Laniquidar. Nateglinide The metabolism of Everolimus can be decreased when combined meds Nateglinide. Bosentan The metabolism of Everolimus can be increased when combined with Bosentan.

Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Everolimus. Lipegfilgrastim Everolimus may increase the myelosuppressive activities of Lipegfilgrastim. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Everolimus.

Everolimus CAS#:

Enasidenib The serum concentration of Everolimus can be increased when it is combined with Enasidenib. Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Everolimus.

Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus. Paricalcitol The everolimuz of Everolimus can be decreased when combined with Paricalcitol.

Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Everolimus. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Everolimus. Nisoldipine The serum concentration of Everolimus can be increased when it is combined with Nisoldipine. Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Everolimus.

Fluvastatin The metabolism of Everolimus can be increased when combined with Fluvastatin. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Everolimus. Edetate disodium anhydrous The risk or severity of bleeding can be increased when Edetate disodium anhydrous is combined with Everolimus.

Avoid ingestion and inhalation. Gefitinib The serum concentration of Everolimus can be increased when it is combined with Gefitinib.

Peldesine The metabolism of Peldesine can be decreased when combined with Everolimus.